Representative Josh Gottheimer (D-New Jersey) recently bought shares of Eli Lilly and Company NYSE: LLY. In a filing disclosed on June 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on May 1st. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.
Representative Josh Gottheimer also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/26/2025.
- Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/25/2025.
- Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 6/25/2025.
- Sold $1,001 - $15,000 in shares of ConocoPhillips NYSE: COP on 6/24/2025.
- Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 6/24/2025.
- Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/24/2025.
- Sold $1,001 - $15,000 in shares of Visa NYSE: V on 6/20/2025.
- Purchased $1,001 - $15,000 in shares of Cloudflare NYSE: NET on 6/20/2025.
- Purchased $1,001 - $15,000 in shares of Carvana NYSE: CVNA on 6/20/2025.
- Sold $1,001 - $15,000 in shares of McDonald's NYSE: MCD on 6/20/2025.
Eli Lilly and Company Stock Up 0.8%
NYSE LLY traded up $6.30 during mid-day trading on Friday, reaching $811.73. The stock had a trading volume of 2,976,064 shares, compared to its average volume of 2,810,305. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The company has a fifty day moving average price of $771.95 and a 200 day moving average price of $800.41. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock has a market cap of $769.31 billion, a PE ratio of 66.05, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same quarter in the previous year, the company posted $2.58 EPS. The company's quarterly revenue was up 45.2% on a year-over-year basis. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.
Eli Lilly and Company Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is 48.82%.
Institutional Investors Weigh In On Eli Lilly and Company
A number of hedge funds have recently bought and sold shares of LLY. PNC Financial Services Group Inc. raised its position in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Eli Lilly and Company by 103,831.6% during the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after acquiring an additional 14,852,076 shares in the last quarter. Norges Bank bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $8,407,908,000. Nuveen LLC bought a new position in shares of Eli Lilly and Company in the first quarter valued at $4,613,912,000. Finally, Proficio Capital Partners LLC grew its position in shares of Eli Lilly and Company by 100,387.1% in the 4th quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock valued at $4,016,110,000 after acquiring an additional 5,197,038 shares during the period. 82.53% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on LLY shares. Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Cantor Fitzgerald began coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 target price for the company. Wall Street Zen lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Saturday, June 28th. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $1,012.56.
View Our Latest Stock Analysis on Eli Lilly and Company
About Representative Gottheimer
Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.
Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election.
Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.
Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
